EP23.31: Assessment of the accuracy and safety of ultrasound guided tru‐cut biopsy in a tertiary hospital from 1 Jan 2021–31 Dec 2022: a retrospective study

To assess the accuracy and safety of tissue diagnosis of advanced ovarian carcinoma using tru-cut biopsy. We used retrospective descriptive purposive sampling technique and 33 patients diagnosed with ovarian malignancy in a tertiary hospital from January 2021 to December 2022 were included. The adequacy rate of the tru-cut biopsy size for histological findings was determined to be 100% while the detection rate was 81.8%. The observed agreement between ultrasound-guided tru-Cut biopsy and cytopathology (Kappa = 83.3%, p = 0.03) was higher than what would be expected by chance alone (Kappa = 55.6%). This ultrasound-guided Tru-cut biopsy has a sensitivity of 87.5% (95% CI: 47.4%, 99.7%), specificity of 75.0% (95% CI: 19.4%, 99.4%), positive likelihood ratio of 3.5 (95% CI: 0.63, 19.50), and a negative likelihood ratio of 0.17 (95% CI: 0.02, 1.14). There were no reported complications which deems Tru-cut biopsy as safe procedure. Tru-Cut biopsy is an accurate and safe alternative procedure with high adequacy rate and detection rate. It is a safe procedure with no complications observed. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.